Literature DB >> 6377284

Stable versus partial response in advanced prostate cancer.

N H Slack, M F Brady, G P Murphy.   

Abstract

Stable response to therapy in patients with advanced prostate cancer, as experienced in clinical trials of the National Prostatic Cancer Project (NPCP), has been reexamined. Data from ten complete trials totaling over 1,300 patients have been examined for survival patterns within categories of response to therapy. Survival patterns, both for all patients and for those alive at 12 weeks, were significantly poorer for patients categorized as progressors after 12 weeks on treatment than for those categorized as stable or as partial regressions. Furthermore, comparisons of survival patterns for those patients categorized as stable or partial regression revealed no statistically significant differences between them. The similarity of survival for the stable and partial regression categories indicates that the stable category represents more than a segment of the population with slowly progressing disease and can be taken as an indicator of response to therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6377284     DOI: 10.1002/pros.2990050405

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

1.  Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.

Authors:  A Veronesi; V Dal Bo; G Lo Re; M Della Valentina; U Tirelli; A Merlo; R Talamini; M Francini; S Monfardini
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.

Authors:  K Kruczek; M Ratterman; K Tolzien; S Sulo; T M Lestingi; C Nabhan
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.